NSCLC (Non-small Cell Lung Cancer), Solid Tumor
Conditions
Keywords
YH42946-101
Brief summary
The goal of this YH42946-101 is to evaluate the safety, Tolerability, Pharmacokinetics and anti-tumor activity of YH42946 in patients with locally advanced of metastatic solid tumors with HER2 aberration and EGFR exon 20 insertions.
Detailed description
YH42946 is a novel, orally available tyrosine kinase inhibitor targeting HER2. YH42946 showed potency for diverse HER2 aberrations including HER2 overexpression, amplification, or mutation, as well as EGFR Ex20ins. This is a Phase 1/2, open-label, multicenter, first-in-human study of YH42946. The study has 2 parts. The first part is dose escalation part to identify the maximum tolerated dose. The second part is dose expansion part to select 2 doses for RD selection at the first cohort, after then RD will be determined to ensure its efficacy. Several independent cohorts are planned.
Interventions
DRUGYH42946
YH42946
Sponsors
Yuhan Corporation
Study design
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* ECOG performance status 0 or 1 * Estimated life expectancy of at least 3 months * Patients who have progressed on or after all available standard therapies or for whom standard treatment is inappropriate * Mandatory provision of archived or fresh tumor tissue in quantity sufficient to allow for retrospective confirmation of HER2 aberration or EGFR mutation * A patient with a history of brain metastases must have had all lesions treated * Adequate organ function defined as all of the following: * Adequate bone marrow function (within 1 week prior to first administration): Neutrophils≥1.5 x10\*9 cells/L (Criteria must be met without the use of Granulocyte-Colony Stimulating Factor (G-CSF) within last week prior to testing.); platelet count≥75 x10\*9 cells/L; Hb ≥9g/dL (Criteria must be met without packed red blood cell (pRBC) transfusion within last week prior to testing.) * Adequate hepatic function: Serum bilirubin≤1.5 x upper limit of normal (ULN), and serum transaminase (either aspartate transaminase (AST) or alanine transaminase (ALT)) ≤ 3 x ULN if no demonstrable liver metastases, or otherwise ≤ 5 x ULN if transaminase elevation is attributable to liver metastases (within 1 week prior to first administration) * Adequate renal function: Serum creatinine ≤ 1.5 x ULN or Estimated glomerular filtration rate (eGFR) \> 60 mL/min per 1.73 m\*2 according to the site's calculation method. * Adequate Heart function: QTcF≤ 470 ms, LVEF≥ 50% * Blood Coagulation: INR or Prothrombin time ≤ 1.5 X ULN, aPTT ≤ 1.5 X ULN \[Dose Escalation part only\] * Histologically or cytologically confirmed diagnosis of advanced, and/or metastatic non-hematologic malignancy * Documented HER2 aberration or EGFR mutation (HER2 mutation or EGFR exon 20 insertion, HER2 amplification or overexpression) \[Dose Expansion part only\] * Patients who have at least 1 measurable lesion * Patients with histologically or cytologically confirmed locally advanced or metastatic NSCLC HER2 exon 20 insertion (Cohort 1)
Exclusion criteria
* Patient with symptomatic or progressive brain metastases * Known or suspected leptomeningeal disease (LMD) * Uncontrolled spinal cord compression * History of acute coronary syndromes, including myocardial infarction, coronary artery bypass graft, unstable angina, coronary angioplasty or stenting within past 24 weeks * History of or current Class II, III or IV heart failure as defined by the New York Heart Association (NYHA) functional classification system * Medical, psychiatric, cognitive or other conditions that compromise the patients ability to understand the patient information, to give informed consent, to comply with the study protocol or to complete the study * Any severe concurrent disease or condition (includes active infections, cardiac arrhythmia) that in the judgment of the Investigator would make study participation inappropriate for the patient * History of (non-infectious) interstitial lung disease (ILD) or pneumonitis that required steroids, or any evidence of current ILD or pneumonitis * History of a second primary cancer with the exception of 1. curatively treated non-melanomatous skin cancer, 2. curatively treated cervical or breast carcinoma in situ, or 3. other malignancy with no known active disease present and no treatment administered during the last 2 years * Infection with Human immunodeficiency virus (HIV) infection, or active chronic hepatitis B or chronic hepatitis C * Major surgery within 4 weeks prior to the first dose of study treatment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Treatment Emergent Adverse Events(TEAE)s | Through study completion, during the first 21 days of DLT evaluation period. | To assess the safety and tolerability of YH42946 |
| Objective Response Rate (ORR) | Through dose expansion part completion, approximately 12 months | Anti-tumor activity according to RECIST v1.1 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| AUClast | Through study completion, approximately 12 months | To characterize the pharmacokinetics (PK) of YH42946 |
| AUCinf | Through study completion, approximately 12 months | To characterize the pharmacokinetics (PK) of YH42946 |
| Cmax | Through study completion, approximately 12 months | To characterize the pharmacokinetics (PK) of YH42946 |
| Tmax | Through study completion, approximately 12 months | To characterize the pharmacokinetics (PK) of YH42946 |
| Objective Response Rate (ORR) | Through study completion, approximately 12 months | To assess the anti-tumor activity according to RECIST v1.1 |
Countries
South Korea, United States
Contacts
CONTACTYuhan Corporation Clinical Operation Team 1
STUDY_DIRECTORJeesun Lee, MD
Yuhan Corporation
Outcome results
None listed